The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Glioblastoma: Overview of Disease and Treatment
Open accessAbstract
BACKGROUND: Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. Current treatment options at diagnosis are multimodal and include surgical resection, radiation, and chemotherapy. Significant advances in the understanding of the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies for recurrent and newly diagnosed disease. Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival. OBJECTIVES: This article reviews the background, risks, common complications, and treatment options for GBM. METHODS: A brief review of GBM, treatment options, and a look at new therapies that have been approved for new and recurrent disease are included in this article. FINDINGS: Despite aggressive resection and combined modality adjuvant treatment, most GBMs recur. Treatments, such as TTFields, drugs to target molecular receptors, and immunotherapy, are promising new options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“Statistically significant associations between greater extent of resection and longer progression-free survival (PFS) and overall survival (OS) have been seen in several studies (Keles, Anderson, & Berger, 1999; Lacroix et al., 2001; Mukherjee & QuiñonesHinojosa, 2011; Stummer et al., 2006).”
BackgroundPhillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Cited by
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., & Wang, R.-F. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1434-3 · Cited by 748
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00963 · Cited by 322
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Fisher, J. P., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030324 · Cited by 316
Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy
Gregory, J. V., Kadiyala, P., Doherty, R., Cadena, M., Habeel, S., Ruoslahti, E., Lowenstein, P. R., Castro, M. G., & Lahann, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19225-7 · Cited by 293
Temozolomide and Other Alkylating Agents in Glioblastoma Therapy
Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines · doi:10.3390/biomedicines7030069 · Cited by 279
Next-generation stem cells — ushering in a new era of cell-based therapies
Kimbrel, E. A., & Lanza, R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0064-x · Cited by 275
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Deng, G., Peng, X., Sun, Z., Zheng, W., Yu, J., Du, L., Chen, H., Gong, P., Zhang, P., Cai, L., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03824 · Cited by 252
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Paolillo, M., Boselli, C., & Schinelli, S. (2018) · Brain Sciences · doi:10.3390/brainsci8010015 · Cited by 135
High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes, R. E., Elliott, R. J. R., Dawson, J. C., & Carragher, N. O. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.015 · Cited by 62
Zhao, F., Zhang, X., Bai, F., Lei, S., He, G., Huang, P., & Lin, J. (2023) · Advanced Materials · doi:10.1002/adma.202208097 · Cited by 41
Pericyte-derived fibrotic scarring is conserved across diverse central nervous system lesions.
Dias, D. O., Kalkitsas, J., Kelahmetoglu, Y., Estrada, C. P., Tatarishvili, J., Ernst, A., Huttner, H. B., Kokaia, Z., Lindvall, O., Brundin, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.30.068965
Down-Regulation of PDCD4 Promotes Proliferation, Angiogenesis and Tumorigenesis in Glioma Cells
Pin, G., Huanting, L., Chengzhan, Z., Xinjuan, K., Yugong, F., Wei, L., Shifang, L., Zhaojian, L., Kun, H., Weicheng, Y., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.593685 · Cited by 18
“Despite the combination of surgery, chemotherapy and radiotherapy, the prognosis of the patients remains poor due to its molecular heterogeneity and high degree of invasiveness (Davis, 2016).”
BackgroundHelweg, L. P., Storm, J., Witte, K. E., Schulten, W., Wrachtrup, L., Janotte, T., Kitke, A., Greiner, J. F. W., Knabbe, C., Kaltschmidt, B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112919 · Cited by 10
Metadata
- Authors
- Davis, M.
- Venue
- Clinical Journal of Oncology Nursing
- Publisher
- Oncology Nursing Society (ONS)
- Published
- 2016-10-01
- Volume
- 20
- Issue
- 5
- Pages
- S2-S8
- ISSN
- 1092-1095 (ISSN-L)
- 1538-067X
- OpenAlex
- W2526011086
- Cited by
- 1,205
- References
- 49
- FWCI
- 31.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.